Hints and tips:
Related Special Reports
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
...Chief executives at AbbVie, Eli Lilly, and Johnson & Johnson all earned more than Soriot in 2023....
...Johnson & Johnson has offered an improved $6.5bn settlement to tens of thousands of plaintiffs claiming that its talcum powder products caused ovarian cancer, in its latest attempt to draw a line under the...
...Johnson & Johnson has struck a deal to buy medical device maker Shockwave Medical for $13.1bn, as the healthcare giant puts cash to work from the spin-off of its consumer health arm to pursue acquisitions...
...Roche, Johnson & Johnson and Denmark’s Genmab have all inked deals this year, following nearly $100bn of ADC-focused M&A and partnership transactions last year....
...Johnson & Johnson had received scorn for executing the so-called Texas Two-Step bankruptcy strategy. The healthcare titan was facing thousands of claims about allegedly carcinogenic talcum powder....
...Johnson & Johnson will ask tens of thousands of plaintiffs claiming the drugmaker’s baby powder and talc-based products led to ovarian cancer to vote in favour of an improved $6.5bn settlement deal, in its...
...Johnson & Johnson has struck a deal to buy medical device maker Shockwave Medical for $13.1bn, as the healthcare giant pursues acquisitions to bolster its medical technology arm....
...Bazini and Macleod now jointly own 41.3 per cent of the company’s shares. While the company’s growth outlook is attractive, the market seems to have priced this in given the current valuation....
Aversion to risk spurs sharp fall to equity ETFs while government bond ETF flows tick up
...and insights to a range of the company’s domestic and international stakeholders”....
...AstraZeneca has agreed to buy oncology biotech Fusion Pharmaceuticals for $2.4bn, as it builds its capacity in a developing field of cancer care....
...“There is also the question of when [holdings] have improved, what are you going to do with these companies? It may become a non-label.”...
Market share of 44% in fast-growing part of industry far exceeds Pimco’s 15% and Fidelity’s 11%
...“There is perhaps a moral aversion to investing in some of these companies [among Republicans],” Cooper said....
...The company noted that nearly 10 per cent of European ETF launches last year were actively managed....
...ETFs accounted for 51 per cent of underlying assets at the end of last year, up from 46.7 per cent in early 2022, according to data from Broadridge Financial Solutions, a financial technology company, which...
Buying spree, which was third-strongest monthly figure since 2021, came even as investors exited tech
...We haven’t had a Standard Oil moment,” Marsh added, alluding to the company that was dismantled by the US government in 1911....
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...More unexpectedly, research by Rutgers University in 2019 concluded that having a similar ticker to that of a large company can reap rewards, with 5 per cent of trades in the smaller entity made by mistake...
...In December, Caracas signed a licence for Shell to operate the Dragon gasfield together with Trinidad and Tobago’s National Gas Company, a deal licensed by the US sanctions body Ofac....
...Shares of consumer health company Kenvue rose 6 per cent after the Johnson & Johnson spin-off beat profit expectations and announced it would cut its workforce by 4 per cent....
...Last year, the company completed a two-year programme designed to transform it from a content provider to a “content-driven” technology company....
...Kenvue, the Johnson & Johnson spin-off, also reports earnings before the opening bell. McKesson and Occidental Petroleum report results after the market closes....
International Edition